OB318
INDICATION
Malignant tumor (Hepatocellular Carcinoma)
MECHANISM OF ACTION
A first-in-class new drug with novel dual inhibitory functions in metastasis and angiogenesis by its high selectivity in anti-cancer activity. The administration of OB318 dramatically reduced tumor size in xenograft mouse models including the hepatoma HepG2, Huh-7, prostate PC3, lung cancer A549 and melanoma B16F10 cell lines.
CURRENT STATUS
1.2020 Phase I clinical trials initiation in Taiwan
2.Before 2020 Phase I study approval by TFDA and FDA
EFFICACY
The administration of OB318 dramatically reduced tumor volume in xenograft mouse models including the hepatoma HepG2, Huh-7, prostate PC3, lung cancer A549 and melanoma B16F10 cells.
MARKET POTENTIAL
Millions of patients with liver cancer die annually and Hepatocellular cancer (HCC) is the most common type of primary liver cancer, accounting for about 90 percent of cases. The currently available treatment options are with limited increase in overall survival and therefore new effective treatment is urgently required to meet the medical need for HCC. The market size for treatment forecasted to be US$5 billion in 2025 (Reference: Nature review)